Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy
- Sponsor
- Seoul National University Bundang Hospital
- Study ID
- NCT00745498
- Status
- Completed
Conditions
- Proliferative Diabetic Retinopathy
- Vitreous Hemorrhage
Eligibility Criteria
- Sex
- ALL
- Age
- 20 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — DRUGPatients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)
Study Details
The purpose of this study is to determine the effect of pre- and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy.
Key Dates
- First listed
- Sep 3, 2008
- Start date
- Jun 30, 2008
- Status verified
- Nov 2015
- Primary completion
- Oct 31, 2010
- Completion
- Oct 31, 2010
Study Design
- Enrollment
- 126 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Preop IVBPatients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 14 days before vitrectomy
- Experimental: Intraop IVBPatients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
- No Intervention: No IVBPatients will not receive bevacizumab before nor during vitrectomy
Primary Outcome Measure
Recurrent VH Incidence (Early and Late) [ Time Frame: 6 months ]